1 week Ago By Defense World Staff
Norges Bank bought a new stake in Pulse Biosciences, Inc. ( NASDAQ:PLSE – Free Report ) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 20,000 shares of the company’s stock, valued at approximately $348,000.
A number of other large investors have also added to or reduced their stakes in PLSE. Vanguard Group Inc. lifted its position in shares of Pulse Biosciences by 15.
1% during the fourth quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company’s stock valued at $19,958,000 after buying an additional 150,506 shares during the last quarter.
Charles Schwab Investment Management Inc. lifted its position in Pulse Biosciences by 193.0% during the third quarter.
Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after acquiring an additional 97,565 shares during the last quarter. State Street Corp lifted its position in Pulse Biosciences by 17.
8% during the third quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after acquiring an additional 69,696 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pulse Biosciences in the third quarter valued at approximately $588,000.
Finally, Geode Capital Management LLC grew its holdings in Pulse Biosciences by 7.8% in the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after purchasing an additional 33,200 shares during the last quarter.
76.95% of the stock is currently owned by institutional investors. Wall Street Analysts Forecast Growth Separately, StockNews.
com upgraded Pulse Biosciences to a “sell” rating in a report on Monday, March 31st. Pulse Biosciences Trading Up 3.1 % Pulse Biosciences stock opened at $16.
04 on Friday. The stock has a 50-day moving average of $17.84 and a two-hundred day moving average of $17.
92. Pulse Biosciences, Inc. has a one year low of $6.
60 and a one year high of $25.00. Pulse Biosciences Company Profile ( Free Report ) Pulse Biosciences, Inc operates as a novel bioelectric medicine company.
The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. Featured Articles Five stocks we like better than Pulse Biosciences How to Buy Gold Stock and Invest in Gold Robinhood Strategies Could Be a Game-Changer for Young Investors Buy P&G Now, Before It Sets A New All-Time High Are These 3 Retail Stocks Oversold or Really in Trouble? How to Invest in Tech Stocks and Top Tech Stocks to Consider IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
